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Abstract 
In vivo real-time epifluorescence imaging of mouse hindlimb vasculatures in the second near-
infrared region (NIR-II, 1.1–1.4 m) is performed using single-walled carbon nanotubes 
(SWNTs) as fluorophores. Both high spatial resolution (~30 m) and temporal resolution (<200 
ms/frame) for small vessel imaging are achieved 1~3 mm deep in the tissue owing to the 
beneficial NIR-II optical window that affords deep anatomical penetration and low scattering. 
This spatial resolution is unattainable by traditional NIR imaging (NIR-I, 0.75–0.9 m) or 
microscopic computed tomography (micro-CT), while the temporal resolution far exceeds 
scanning microscopic imaging techniques. Arterial and venous vessels are unambiguously 
differentiated using a dynamic contrast-enhanced NIR-II imaging technique based on their 
distinct hemodynamics. Further, the deep tissue penetration, high spatial and temporal resolution 
of NIR-II imaging allow for precise quantifications of blood velocity in both normal and 
ischemic femoral arteries, which are beyond the capability of ultrasonography at lower blood 
velocity. 
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Introduction 
Development of new therapies for peripheral arterial diseases (PADs) may be facilitated by 
imaging that provides anatomic and hemodynamic information with high spatial and temporal 
resolution. However, current methods for assessing vasculature and hemodynamics in small 
vessels in vivo are suboptimal.
1
 For imaging vascular structures, microscopic computed 
tomography (micro-CT) and magnetic resonance imaging (MRI) can resolve features down to 
~100 m with deep penetration, but are limited by long scanning and post-processing time and 
difficulties in assessing vascular hemodynamics.
2,3
 On the other hand, vascular hemodynamics 
are usually obtained by Doppler measurements of micro-ultrasonography with high temporal 
resolution of up to 1000 Hz, but spatial resolution attenuates with increased depth of 
penetration.
4
  
In vivo fluorescence-based optical imaging has inherent advantages over tomographic 
imaging owing to high temporal and spatial resolution.
5,6
 Single-walled carbon nanotubes 
(SWNTs), nanoscale cylinders of rolled-up graphite sheets comprised of carbon, are an emerging 
nanomaterial with unique optical properties for in vivo anatomical imaging,
7,8
 tumor detection
9,10
 
and photothermal treatment.
10-12
 One unique feature of SWNTs is their intrinsic fluorescence in 
the second near-infrared (NIR-II, 1.1–1.4 m) window upon excitation in the traditional near-
infrared region (NIR-I, 0.75–0.9 m) with large Stokes shift up to ~400 nm. Compared to the 
NIR-I window that has been extensively explored for in vitro and in vivo imaging,
13-18
 the longer 
wavelength emission in NIR-II makes SWNTs advantageous for imaging owing to reduced 
photon absorption
19,20
 and scattering by tissues,
8,21
 negligible tissue autofluorescence and thus 
deeper tissue penetration,
7,8,22
 allowing for unprecedented fluorescence-based imaging resolution 
of anatomical features deep to the skin.  
 Here we report the use of biocompatible, brightly fluorescent SWNTs as NIR-II imaging 
agents for imaging vascular structures down to ~30 m in mouse hindlimb using an 
epifluorescence imaging method with an indium-gallium-arsenide (InGaAs) imaging system. 
Compared to micro-CT, NIR-II fluorescence imaging attains a ~3-fold improvement in spatial 
resolution. Further, NIR-II imaging allows for differentiation of arteries from veins through 
principal component analysis (PCA)
8,23
 to obtain dynamic contrast-enhanced imaging. We can 
also quantify femoral artery blood flows in both normal and ischemic hindlimbs, and reveal the 
degree of occlusion due to ischemia. Thus, a single NIR-II imaging modality enables multi-
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functional imaging capable of accomplishing what is typically done by several traditional 
techniques including micro-CT, ultrasonography and MRI, making it a unique method that 
incorporates many desirable features such as high spatial resolution (~30 m), fast acquisition 
(<200 ms), good tissue penetration (1~3 mm), vessel specification and blood flow quantification.   
Results 
NIR-I and NIR-II fluorescence imaging of vasculatures. First, to glean the differences of in 
vivo NIR-I and NIR-II fluorescence imaging, we made biocompatible SWNT-IRDye-800 
conjugates as dual-color imaging agents, where IRDye-800 (IRDye 800CW, LI-COR) was a 
commercial NIR-I fluorophore. High-pressure carbon monoxide conversion (HiPCO) SWNTs 
were stably suspended by biocompatible surfactants of 75% DSPE-mPEG (5kDa) and 25% 
DSPE-PEG(5kDa)-NH2 with amine groups covalently functionalized with IRDye-800 (Figs. 1a 
and S1a-c). Both the SWNT and IRDye-800 label could be excited by a 785 nm laser, but 
exhibited different emissions. The IRDye-800 dye emitted at ~800 nm in the NIR-I, while the 
SWNT emitted in the 1.1–1.4 m NIR-II region (Fig. 1b). The dual-color emission of SWNT-
IRDye-800 conjugate ensured co-localization of SWNTs and IRDye-800 dyes, and enabled us to 
image the same tissue in two distinct spectral windows so as to evaluate the performance of 
photons in different wavelengths for live animal imaging.  
For parenteral administration and live animal imaging, we prepared and injected a 
solution (200 L) of 0.10 mg·mL-1 (1.0 mg·kg-1 body weight) SWNT-IRDye-800 conjugates 
(Fig. 1c) into a nude mouse intravenously. We estimated the maximum SWNT concentration in 
the blood would be 17× lower than the half maximal inhibitory concentration (IC50) of vascular 
endothelial cells (Fig. S1d). The circulation half-time of DSPE-mPEG functionalized SWNTs 
was ~5 h,
8
 and our previous studies had shown the lack of acute or long-term toxicity of such 
PEGylated SWNTs in vivo.
10,24,25
 The mouse was illuminated using a 785 nm laser at 8 mW·cm
-2
 
(Fig. 1d) and imaged in the NIR-I (Fig. 1e–g) using a Si camera and in the NIR-II (Fig. 1h–j) 
using an InGaAs camera equipped with different emission filters. An adjustable lens set was 
used to obtain three different magnifications: 1× (whole body), 2.5× (entire hindlimb) and 7× 
(partial hindlimb).  
We found that all images in the NIR-I region employing IRDye-800 fluorescence 
manifested indistinct vascular anatomy. The corresponding cross-sectional intensity profiles 
were characterized by broad peaks (Fig. 1e–g, bottom). Presumably, these characteristics were 
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related to significant scattering and absorbance of NIR-I photons, which limited the depth and 
resolution of traditional NIR imaging in vivo.
8
 In contrast, when the same mouse was imaged in 
the NIR-II region by detecting SWNT fluorescence, there was a substantially improved spatial 
resolution of vessels at all magnifications. Moreover, the NIR-II window clearly visualized 
smaller, higher-order branches of blood vessels at higher magnifications. Cross-sectional 
intensity profiles all exhibited sharp peaks, with the calculated vessel diameter values consistent 
with expected values (Fig. 1h–j, bottom). In contrast, it was impossible to calculate vessel 
diameters based on the NIR-I images, in which we observed a 2~3-fold broadening of the cross-
sectional profiles on average. 
NIR-II and micro-CT for vessel imaging. Micro-CT is a commonly-used three-dimensional 
(3D) X-ray imaging technique based on tomographic reconstruction with spatial resolution down 
to ~100 m and excellent penetration depth.26,27 Accordingly, we compared the spatial resolution 
of the proximal femoral artery and vein in the same mouse, achieved by NIR-II and micro-CT 
methods (Fig. 2a,b). A cross-sectional analysis was performed across the blood vessels in each 
image, and the corresponding intensity profiles are shown for NIR-II image (Fig. 2c) and micro-
CT image (Fig. 2d). Two peaks were identified in each plot, corresponding to femoral artery and 
vein, and were fitted into two Gaussian functions to extract the widths. The vessel widths 
extracted from NIR-II image (0.284 mm and 0.255 mm) agreed with those from micro-CT image 
(0.292 mm and 0.247 mm). The analysis of micro-CT images validated the vessel diameters 
measured by NIR-II imaging, suggesting the two techniques are comparable in imaging vascular 
structures ~100s m in diameter. 
To compare the resolution limits between NIR-II and micro-CT, we determined the 
smallest vessels these two techniques were able to discern. In the distal hindlimb of the mouse, 
the NIR-II image showed greater numbers of small vessels compared to the micro-CT image at 
the same location (Fig. 2e,f). The smallest measurable vessel by NIR-II had a Gaussian-fit 
diameter of only 35.4 m (Fig. 2g), while micro-CT could not discern any vessel smaller than 
~100 m in diameter (Fig. 2h). Furthermore, NIR-II method generated images much faster than 
micro-CT (300 ms for NIR-II and 2 h for micro-CT).  
Differentiation of arterial and venous vessels. To determine whether NIR-II fluorescence 
imaging could distinguish arterial from venous circulation, we monitored the blood flow inside 
the vessels by recording videos in the NIR-II window immediately upon tail-vein injection of 
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SWNT fluorophores. To enable greater temporal resolution (i.e., shorter exposure time) for 
dynamic recordings, we used an 808 nm laser at 140 mW·cm
-2
 for more efficient excitation of 
SWNT fluorophores. 
 When a 200 L solution containing 0.10 mg·ml-1 biocompatible SWNTs was injected 
into the tail vein of a nude mouse (Mouse C1), we observed an NIR-II signal from the SWNTs in 
the proximal femoral artery within 5 s, and the entire femoral artery and some of the proximal 
musculature after ~8 s (Fig. 3a,b). Outflow of SWNTs into the femoral vein was reflected by the 
increased feature width (vascular bundle in the femoral sheath) at later time points but difficult to 
distinguish from the femoral artery by visual inspection due to their proximity (Fig. 3c). 
However, due to the time delay in the first appearance of the signal in the artery to its later 
appearance in the vein (Movie S1), it was possible to employ PCA to differentiate the two types 
of vessels.
8,23
 Essentially, the PCA approach assigns image pixels to groups (components) based 
on their variance, i.e., pixels that vary similarly in time. We applied PCA to the video-rate 
images and clearly discriminated the arterial component from the venous component. By 
convention we color-coded the arterial PCA component in red and the venous component in blue 
(Fig. 3d). Similar results were obtained with an additional three mice (Figs S2a-f). 
We repeated these studies in mice after surgically inducing unilateral hindlimb ischemia 
(Mouse I1–3). In this model, ligation and excision of the proximal superficial femoral artery and 
ligation of the deep femoral artery reduced limb perfusion by ~80% in the immediate 
postoperative period.
28
 On the first postoperative day, we studied mice with SWNT-assisted 
NIR-II fluorescence imaging. After tail vein injection of SWNTs, we observed a marked delay in 
the appearance of fluorescent signals in ischemic limbs (Fig. 3e-g) compared to healthy limbs. 
As in normal animals, we performed PCA on the first 200 frames (~37.5 s) of video-rate 
recording (Movie S2) of the ischemic animal. However, due to the markedly reduced perfusion, 
venous return in the ischemic limb could not be observed at this time point (Figs. 3h and S2g-j). 
It was necessary to continue imaging for an extended period (>2 min) to visualize the femoral 
vein (Fig. S3 and Movie S3). This delay in venous return was consistent with severe limb 
ischemia. 
We also applied the dynamic contrast PCA approach to demonstrate that arteries and 
veins subserving a larger region of tissue could be distinguished. In these studies, we imaged a 
larger field of view including both the abdominal and femoral regions. Within 5 s of tail vein 
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injection (Movie S4), signals were observed in the aorta as well as the iliac, femoral and 
epigastric arteries and their branches in the abdomen and pelvis (Fig. 4b). The NIR-II signal 
from these vessels peaked and then subsided by ~10 s post injection with increasing intensity in 
the tissue (Fig. 4c). Subsequently, signals were observed in veins draining these regions, 
including the previously identified femoral vein and hypogastric veins (Fig. 4d). As before, we 
used PCA to assign pixels to arterial or venous conduits based on their time variance (Fig. 4e), 
where arteries and veins were resolved. Notably, even the aorta can be seen in supine position of 
the mouse, indicating a penetration depth of >5 mm for NIR-II imaging. This result confirmed 
the capacity of NIR-II dynamic contrast-enhanced imaging to distinguish arteries from veins. 
Blood flow quantification in ischemic and control limbs. NIR-II imaging revealed a dramatic 
delay in the appearance of fluorescence signal in ischemic hindlimbs versus control healthy 
limbs. We then assessed blood flow in the ischemic hindlimb of Mouse I1 quantitatively. From 
12 s to 19.5 s post injection of SWNTs, propagation of the signal could be visualized from the 
proximal site of arterial occlusion to the distal femoral artery (Fig. 5a), presumably filling 
through collateral channels. The position of the signal front at each time point was then extracted 
from each frame and plotted against time, showing a linear relationship of flow distance vs. time 
with a blood velocity of 0.163 cm·s
-1
 (Fig. 5b). To calculate blood flow, we measured the mean 
diameter of the femoral artery (174 m). The measurement of blood flow velocity and arterial 
diameter permitted the calculation of femoral artery blood flow (2.33x10
-3
 mL·min
-1
). 
We found the progression of NIR-II signal through the femoral artery in normal mice was 
so rapid that our current video imaging rate lacked sufficient temporal resolution. Alternatively, 
to assess blood velocity in these animals, we measured the increase in signal intensity in a region 
of interest (ROI) (a pre-defined segment of the femoral artery from PCA). We normalized the 
signal intensity to compensate for differences in actual injected dose or fluorescence quantum 
yield, and plotted the average ROI intensity vs. time (see Methods). In the animal with hindlimb 
ischemia, we observed an NIR-II intensity increase of 2.18%·s
-1
 (Fig. 5c). Blood flow and NIR-
II intensity were then plotted against each other (Fig. 5d) to yield a linear slope of ~0.0737 
cm·%
-1
 that correlated velocity with intensity change. We used this coefficient to convert the 
NIR-II intensity increase rate to blood velocity, in the normal animals where blood velocity 
exceeded the temporal resolution of our current imaging device. To further establish this 
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translation coefficient, we reproduced the blood velocity quantification with two other ischemic 
mice, I2 and I3, and obtained an average value of 0.0747±0.0019 cm·%
-1
 (Fig. S4 and Table 1). 
 The intensity-to-velocity conversion coefficient was applied to measurements of femoral 
artery blood flow in a healthy, control mouse, where the blood velocity was so rapid that our 
current NIR-II imaging device was unable to track a discrete flow front over time (Fig. 5e). 
Alternatively we measured the NIR-II intensity change in an ROI of the femoral artery as a 
function of time (Fig. 5f), revealing a normalized NIR-II intensity increase of 68.7±5.2%·s
-1
 
before it peaked. By using the conversion coefficient of 0.0747 cm·%
-1
, we were able to translate 
the intensity increase to a blood velocity of 5.13±0.39 cm·s
-1
. To validate this measure of blood 
velocity, we used ultrasonography to obtain a Doppler-derived velocity in the same mouse at the 
same ROI of the femoral artery, by an operator blinded to the SWNT imaging values. In the 
same animal, the ultrasound measurement provided a Doppler-derived velocity of 4.97±0.17 
cm·s
-1
 (Fig. 5g), which was in good agreement with the NIR-II video-imaging result (a deviation 
of ~3%). 
To further validate our intensity-to-velocity conversion coefficient and to understand the 
physics behind it, we used a simplified fluid dynamic system, in which SWNT solution was 
pumped into catheter tubing filled with purified water (Fig. S5k), and derived the coefficient 
based on NIR-II intensity increase (see Methods). By changing the experimental settings one at a 
time, we found the coefficient remained invariant (0.0764±0.0025 cm·%
-1
) as we varied the 
injected SWNT concentration, SWNT fluorescence quantum yield, tubing diameter, ROI length 
and velocity. It did vary with the distance between the injection site and ROI (pre-ROI length) 
(Fig. S5a-j and Table 2). This finding was also confirmed by numerical simulations (Fig. S5l-s 
and Table 2) based on a linear flow model with axial mixing.
29
 In the context of in vivo blood 
velocity quantification, since the pre-ROI length simply reflected the length of blood vessels in 
which the injected SWNTs had to travel before reaching the femoral artery, the coefficient 
should be invariant given the same type of animals with roughly same blood volume and 
therefore applicable from ischemic to control mice. 
To demonstrate the reproducibility of the NIR-II fluorescence-based blood velocity 
quantification, we compared the Doppler-derived velocities to those of the NIR-II method in 
three additional control animals (Fig. S6). A summarized plot suggested excellent agreement of 
results between the two methods (Fig. 5h). Subsequently, we performed these studies in three 
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ischemic mice. The marked reduction in blood velocity in ischemic limbs (Fig. 5i) measured by 
NIR-II method was consistent with previous reports.
28,30,31
 It was noteworthy that blood velocity 
in the ischemic animals was low and beyond the detection capability of ultrasonography. Clearly, 
the NIR-II imaging technique proved advantageous over ultrasound by providing a broader 
dynamic range of blood velocity measurements in vivo. 
Discussion 
Current methodologies for physiological imaging of PADs are suboptimal in that no 
single modality provides adequate spatial and temporal resolution to accurately assess all critical 
parameters, i.e. vascular structure, arterial inflow, venous outflow, and tissue perfusion. NIR-II 
imaging technique simultaneously provides anatomical and hemodynamic information and 
surpasses the need to use multiple imaging modalities to obtain equivalent data, owing to 
reduced tissue scattering and deeper anatomical penetration of NIR-II over shorter wavelengths. 
This is due to the inverse wavelength dependence (~-1.1) of photon scattering as they travel 
through subcutaneous tissue and skin.
8
  
NIR-II imaging compares favorably to micro-CT. Even with voxel dimensions of 40 m, 
micro-CT was only capable of resolving vessels of ~100 m, while NIR-II could distinguish 
vessels ~3× smaller, without obvious background signal from soft tissue. In terms of imaging 
depth, NIR-II can achieve a penetration depth of millimeters in vivo without losing fidelity of the 
vessel structures, whereas micro-CT is able to reconstruct the whole-body structure in 3D owing 
to the unlimited penetration of X-rays. The time required for micro-CT (hours) as opposed to 
NIR-II imaging (sub-second) also means longer anesthesia time and high radiation doses, 
carrying risks of nephrotoxicity, anaphylaxis, and tissue injury.
32,33
 
NIR-II imaging has three salient advantages over ultrasonography. First, NIR-II is able to 
image smaller vessels. Even with a high frequency (40 MHz) transducer, the diameter of mouse 
vessels could not be accurately determined with ultrasound, due to poor spatial resolution and 
low contrast. Second, NIR-II imaging is able to resolve both arterial and venous vessels 
anatomically and hemodynamically using PCA. Third, NIR-II imaging can be used to acquire 
hemodynamic data in conditions of reduced flow (e.g., ischemic hindlimb), below the detection 
limit of ultrasonography.   
Due to the many benefits of NIR-II fluorescence imaging over other pre-clinical imaging 
modalities, this dual-modality method may be useful in a variety of cardiovascular models. 
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Although our current work focused on assessing blood flow of small vessels, NIR-II imaging 
could be used to characterize in vivo the degree of stenosis or aneurysmal dilation of vessels. 
Because of its temporal resolution, it might also be useful for imaging dynamic changes in vessel 
diameter due to active vasodilation or vasoconstriction. It is conceivable that NIR-II fluorescence 
imaging with SWNTs and other novel NIR-II fluorophores including quantum dots
34,35
 and 
synthetic organic dyes
36
 could lead to many translational and clinical applications. 
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Figures 
 
Figure 1 NIR-I and NIR-II fluorescence imaging of blood vessels in the mouse.  (a) A schematic showing 
that upon excitation of a 785 nm laser, the SWNT-IRDye-800 conjugate emits at the ~800 nm NIR-I 
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region from IRDye-800 dye and the 1.1–1.4 m NIR-II region from the SWNT backbone. (b) Absorption 
spectrum of the SWNT-IRDye-800 conjugate (black dashed curve), emission spectrum of IRDye-800 dye 
(green solid curve) and SWNTs (red solid curve). (c) A digital camera photograph (left) and an NIR-II 
fluorescence image of injected solution containing 0.10 mg·ml
-1
 SWNT-IRDye-800 conjugates. (d) 
Schematic of the imaging setup for simultaneous detection of both NIR-I and NIR-II photons using Si and 
InGaAs cameras. A zoomable lens set was used for adjustable magnifications. (e–g) NIR-I fluorescence 
images (top) and cross-sectional fluorescence intensity profiles (bottom) along red-dashed bars of a 
mouse injected with the SWNT-IRDye-800 conjugates. Gaussian fits to the profiles are shown in red 
dashed curves. (h–j) NIR-II fluorescence images (top) and cross-sectional fluorescence intensity profiles 
(bottom) along red-dashed bars of a mouse injected with the SWNT-IRDye-800 conjugates. Gaussian fits 
to the profiles are shown in red dashed curves. 
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Figure 2 NIR-II fluorescence and micro-CT imaging of hindlimb blood vessels. (a) A NIR-II SWNT 
fluorescence image of a mouse thigh. (b) A micro-CT image showing the same area of the thigh as in a. 
(c) A cross-sectional fluorescence intensity profile measured along the green dashed bar in a with its two 
peaks fitted to Gaussian functions. (d) A cross-sectional intensity profile measured along the green 
dashed bar in b with its two peaks fitted to Gaussian functions. (e) An NIR-II image at the level of the 
gastrocnemius. (f) A micro-CT image showing the same area of the limb as in e. (g) A cross-sectional 
fluorescence intensity profile measured along the green dashed bar in e with its peak fitted to a Gaussian 
function. (h) A cross-sectional intensity profile measured along the green dashed bar in f with its peak 
fitted to a Gaussian function.  All scale bars indicate 2 mm.  
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Figure 3 Differentiation of femoral artery from vein in normal and ischemic mice by NIR-II imaging. (a–
c) Time course NIR-II fluorescence images of hindlimb blood flow in a control healthy animal. (d) PCA 
overlaid image based on the first 200 frames (37.5 s post injection) of the control animal, where arteries 
are color-coded in red, while veins are color-coded in blue. (e–g) Time course NIR-II fluorescence 
images of hindlimb blood flow in an ischemic animal. (h) PCA overlaid image based on the first 200 
frames (37.5 s post injection) of the ischemic animal; only arterial vessels (color-coded in red) can be 
seen. The level of the experimentally induced arterial occlusion is indicated by the yellow arrow. All scale 
bars indicate 2 mm. 
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Figure 4 Differentiation of multiple arterial and venous vessels subserving a larger region of tissue. (a–d) 
Time course NIR-II fluorescence images showing blood flow labeled by SWNT fluorescent tags. (e) PCA 
overlaid image based on the first 170 frames (31.875 s post injection) of the mouse, where arterial vessels 
are shown in red, while venous vessels are shown in blue. The scale bar indicates 5 mm. (f) A digital 
camera photograph of the mouse imaged in supine position beside a ruler.  
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Figure 5 Femoral artery blood velocity quantification for an ischemic hindlimb and a healthy, control 
hindlimb by NIR-II imaging and ultrasound. (a) Time course NIR-II images showing the flow front 
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(marked by a red arrow) in the hindlimb of an ischemic mouse, Mouse I1. The yellow arrow indicates the 
arterial occlusion. (b) Distance travelled by the flow front versus time. (c) Normalized NIR-II signal in 
the femoral artery versus time. (d) Linear correlation between the artery blood velocity and NIR-II 
fluorescence increase in femoral artery. (e) Time course NIR-II fluorescence images showing the NIR-II 
intensity increase in the femoral artery of a control mouse, Mouse C1. (f) Normalized NIR-II signal in the 
femoral artery versus time. (g) Ultrasound measurement of femoral artery blood velocity in Mouse C1 
(top) based on integration of three outlined pulses (bottom). (h) Side-by-side comparison of femoral 
artery velocity obtained from NIR-II method (black) and ultrasonography (gray) for four control healthy 
mice. Black error bars were based on linear-fitting errors of NIR-II intensity increase plot, while gray 
error bars reflected the s.d. of three integrated pulses from ultrasonography. (i) Average femoral artery 
blood velocity of control group (n=4) and ischemic group (n=3), measured by NIR-II method (black) and 
ultrasound technique (gray). The ischemic blood velocity was not measurable by ultrasonography (shown 
as ‘N/A’). Errors bars reflect the s.d. of each group. Scale bars in a and e indicate 5 mm, and the intensity 
scale bar ranges from 0 to 1 for normalized NIR-II fluorescence intensity. 
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Tables 
Table 1 Establishing the intensity-to-velocity conversion coefficient for translating NIR-II signal increase 
to blood velocity. Three ischemic mice, Mouse I1–3, were analyzed based on their blood flow behaviors 
with SWNTs as NIR-II fluorescence tags.  
Ischemic mouse number 
Conversion coefficient 
[cm·%
-1
] 
1 0.0737 
2 0.0773 
3 0.0730 
Average 0.0747±0.0019 
 
 
Table 2 Dependency of the intensity-to-velocity conversion coefficient on six different variables based on 
experimental tubing flow results (left column) and numerical simulation (right column), suggesting the 
coefficient is independent of SWNT concentration, SWNT quantum yield, tubing diameter, ROI length 
and fluid velocity, while only influenced by the pre-ROI length. 
Variable Control Experimental Results [cm·%
-1
] Simulation Results [cm·%
-1
] 
Standard Settings 0.0778 0.0730 
Change SWNT concentration 0.0739 0.0730 
Change SWNT quantum yield 0.0756 0.0730 
Change tubing diameter 0.0766 0.0730 
Change ROI length 0.0789 0.0780 
Change fluid velocity 0.0757 0.0722 
Change pre-ROI length 0.1648 0.1701 
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Methods 
Preparation of water soluble SWNT-IRDye-800 bioconjugate. The preparation of water soluble and 
biocompatible SWNTs can be found in detail in another publication of our group with some 
modification.
37
 In general, raw HiPCO SWNTs (Unidym) were suspended in 1 wt% sodium deoxycholate 
aqueous solution by 1 hour of bath sonication. This suspension was ultracentrifuged at 300,000 g to 
remove the bundles and other large aggregates, the supernatant was retained and 0.75 mg·ml
-1
 of DSPE-
mPEG(5 kDa) (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol, 
5000)], Laysan Bio) along with 0.25 mg·ml
-1
 of DSPE-PEG(5 kDa)-NH2 (1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[amino(polyethyleneglycol, 5000)], Sunbright) was added. The resulting 
suspension was sonicated briefly for 5 min and then dialyzed at pH 7.4 in a 3500 Da membrane (Fisher) 
with a minimum of six water changes and a minimum of two hours between water changes. To remove 
aggregates, the suspension was ultracentrifuged again for 1 hour at 300,000 g. This surfactant-exchanged 
SWNT sample has lengths ranging from 100 nm up to 2.0 μm with the average length of ~500 nm. These 
amino-functionalized SWNTs were further conjugated with IRDye-800 dye molecule according to the 
protocol that has been used in our group.
38
 Briefly, an SWNT solution with amine functionality at 300 nM 
after removal of excess surfactant was mixed with 0.1 mM IRDye-800 NHS ester (LI-COR) in PBS at pH 
7.4. The reaction was allowed to proceed for 1 h before purification to remove excess IRDye-800 by 
filtration through 100-kDa filters. The as-made SWNT-IRDye-800 conjugate solution was kept at 4 °C 
and away from light to avoid photobleaching of IRDye-800 fluorescence. 
UV-Vis-NIR absorption measurements. UV-Vis-NIR absorption spectrum of the as-made SWNT-
IRDye-800 bioconjugate was measured by a Cary 6000i UV-Vis-NIR spectrophotometer, background-
corrected for contribution from water. The measured range was 500-820 nm. 
NIR fluorescence spectroscopy of SWNT-IRDye-800 bioconjugate. NIR fluorescence spectrum was 
taken using a home-built NIR spectroscopy setup. The excitation source was a 200 W ozone-free 
mercury/xenon lamp (Oriel), which was dispersed by a monochromator (Oriel) to generate an excitation 
line with a central wavelength of 785 nm and a bandwidth of 15 nm. The excitation light was allowed to 
pass through the solution sample in a 1 mm path cuvette (Starna Cells, Inc.) and the emission was 
collected in a transmission geometry. The excitation light was rejected using a 790-nm long-pass filter 
(Semrock) so that the fluorescence of both IRDye-800 and SWNTs could be collected in the 790-1500 nm 
emission range. The emitted light was directed into a spectrometer (Acton SP2300i) equipped with a 
liquid-nitrogen-cooled InGaAs linear array detector (Princeton OMA-V). Spectra were corrected post-
collection to account for the sensitivity of the detector and extinction feature of the filter using the 
MATLAB software. 
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Determination of cytotoxicity of SWNTs. We determined the SWNT toxicity in vitro by MTS assay 
using a CellTiter96 kit (Promega) on human dermal microvascular endothelial cells (Lonza). ~5000 cells 
were incubated per well with 100 μl of EGM2MV growth media (Lonza) and serially diluted SWNT 
solution (n=3 for each concentration). The cells were kept at 37 °C in a humidified atmosphere containing 
5% CO2 for 24 hours in the presence of SWNTs at different concentrations. Immediately before addition 
of 15 μL of CellTiter96, a colorimetric indicator of cell viability, the SWNT spiked medium was removed 
from each well plate and replaced with fresh medium. This prevented any interference in the absorbance 
readings from SWNTs. After 1 hour, the color change was quantified using a plate reader and taking 
absorbance readings at 490 nm. Cell viability was plotted as a fraction of the absorbance of control wells 
incubated without SWNTs. 
Mouse handling, surgery and injection. 6-week-old female athymic nude mice were obtained from 
Charles River. All animal studies were approved by Stanford University’s Administrative Panel on 
Laboratory Animal Care. Induction of unilateral hindlimb ischemia was performed according to our 
previous studies.
28,30,39
 Control, unsurgerized mice (n=4) and mice with induced ischemia (n=3) were used 
in the study. For the injection of nanotube solution, a 28 gauge syringe needle was inserted into the lateral 
tail vein, allowing for bolus injection during the first frames of imaging. All mice were initially 
anesthesized before imaging in a knockdown box with 2 L·min
-1
 O2 gas flow mixed with 3% Isoflurane.  
A nose cone delivered 1.5 L·min
-1
 O2 gas and 3% Isoflurane throughout imaging.   
In vivo NIR fluorescence imaging with tunable magnifications. Animals were mounted on a heated 
stage in the supine position beneath the laser at 10 min post injection. NIR fluorescence images were 
collected using a 1344 × 1024 pixel silicon CCD camera (Hamamatsu) for collecting photons in NIR-I 
and a liquid-nitrogen-cooled, 320 × 256 pixel two-dimensional InGaAs array (Princeton Instruments) for 
collecting photons in NIR-II. A flip mirror was used to switch photon collection between the two cameras 
(Fig. 1d). The excitation light was provided by a 785-nm diode laser (Renishaw) coupled to a 4.5-mm 
focal length collimator (Thorlabs) and filtered by a 790-nm bandpass filter with a bandwidth of 10 nm 
(Thorlabs). The excitation power density at the imaging plane was 8 mW·cm
-2
, much lower than the safe 
exposure limit of 296 mW·cm
-2
 at 785 nm determined by the International Commission on Non-ionizing 
Radiation Protection.
40
 The emitted light from the animal was filtered through a 790-nm long-pass filter 
(Semrock) and an 850-nm short-pass filter (Thorlabs) coupled with the Si camera for the NIR-I imaging 
window, or through a 900-nm long-pass filter (Thorlabs) and an 1100-nm long-pass filter (Thorlabs) 
coupled with the InGaAs camera for NIR-II imaging. A lens set was used for obtaining tunable 
magnifications, ranging from 1× to 2.5× magnification by changing the relative position of two NIR 
achromats (200 mm and 75 mm, Thorlabs), and from 2.5× to 7× magnification by changing the relative 
position of two other NIR achromats (150 mm and 200 mm, Thorlabs). A binning of 4 and an exposure 
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time of 300 ms were used for the Si camera (1344 × 1024 pixels) to capture images in the NIR-I window, 
and a binning of 1 and an exposure time of 300 ms were used for the InGaAs camera (320 × 256 pixel) to 
capture images in the NIR-II window. Different binnings were used to compensate the difference of array 
size of the two cameras. 
Microscopic computed tomography for vascular imaging. Micro-CT scans were performed using a 
MicroCAT II micro-CT scanner (Siemens Preclinical Solutions) using the following parameters: X-ray 
voltage 80 kVp, anode current 50 mA, and exposure time 2000 ms per 576 frames through 360° rotation. 
Mice were injected with blood pool contrast agent Fenestra VC (50 mg·ml
-1
 iodine, Advanced Research 
Technologies) intravenously into the lateral tail vein at 0.3 ml·(20 g)
-1
 body weight with a 28-gauge 
needle. Animals (n=2) were scanned 1 h post-injection for 1 h total scan time. Three-dimensional 
reconstruction was performed by COBRA 1.5 and visualized using Amira 5.4. Resulting voxel dimension 
was 40 m. 
Video-rate imaging in the NIR-II window. Video-rate imaging was performed on the same homebuilt 
imaging system as in the steady-state imaging case except that only an InGaAs camera was used for 
imaging in the NIR-II window. The excitation light was provided by an 808-nm diode laser (RMPC 
lasers) coupled to a 4.5-mm focal length collimator (Thorlabs) and filtered by an 850-nm short-pass filter 
and a 1000-nm short-pass filter (Thorlabs). The excitation power density at the imaging plane was 140 
mW·cm
-2
, lower than the safe exposure limit 329 mW·cm
-2
 at 808 nm.
40
 The emitted light from the 
animal was filtered through a 900-nm long-pass filter and an 1100-nm long-pass filter (Thorlabs) so that 
the intensity of each pixel in the InGaAs 2D array represented light in the 1.1~1.7 m range. A lens pair 
consisting of two achromats (200 mm and 75 mm, Thorlabs) was used focus the image onto the detector 
with a magnification of 2.5×. The InGaAs camera was set to expose continuously, and NIR-II 
fluorescence images were acquired with LabVIEW software. The exposure time for all images shown in 
the videos was 100 ms. There was an 87.5-ms overhead in the readout, leading to an average time of 
187.5 ms between consecutive frames and a frame rate of 5.3 frames·s
-1
. 
Dynamic contrast-enhanced imaging based on PCA. Dynamic contrast-enhanced images were 
obtained in a similar fashion to previous work by the Hillman group
23
 and our group.
8
 First 200 
consecutive frames immediately after injection were loaded into an array using MATLAB software, and 
the built-in princomp function was used to perform PCA. Empirically features showing up early in the 
video are grouped in the negative fourth principal component and features showing up later in the video 
are grouped in the negative second principal component. Therefore negative pixels for the second 
principal component were color-coded in blue to represent venous vessels while negative pixels for the 
fourth principal component were color-coded in red to represent arterial vessels. 
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Quantification of blood velocity and flow based on NIR-II fluorescence. Average region of interest 
(ROI) NIR-II fluorescence intensity was computed using MATLAB software within a given arterial 
region of each frame, which was determined by PCA analysis as explained in previous Methods sections. 
Then the NIR-II fluorescence intensity was plotted as a function of time to reveal the change over 4 min 
after intravenous injection. The intensity in the femoral artery increased rapidly within the first 5-10 s 
before residing. The NIR-II intensity values were normalized against the maximum intensity within the 
ROI time traces to compensate for any differences in actual injection dose and relative fluorescence 
quantum yield. Linear fit was then performed on the rising edge of the normalized plot, and its slope (in 
%·s
-1
) was translated into blood velocity in terms of cm·s
-1
 by using the intensity-to-velocity conversion 
coefficient. Since the NIR-II signal increase was averaged over the ROI, the velocity value was the mean 
blood flow velocity along the femoral artery. Blood flow (F) in ml·min-1 (cm3·min-1) was calculated based 
on the blood velocity (V) in cm·s
-1
 and the diameter of the vessel (d) in m as follows: F = π*(d/2)2 * V * 
6*10
-7
. 
Validation of intensity-to-velocity coefficient based on tubing flow model. A solution of SWNTs with 
known concentration was pumped by a syringe pump into catheter tubing with known diameter filled with 
purified water at a preset velocity (Fig. S5k). The following settings were used for the standard condition: 
SWNT concentration = 0.10 mg·ml
-1
, SWNT fluorescence quantum yield (QY) ~ 2.5%, tubing diameter = 
760 m, tubing length within ROI (i.e., ROI length) = 2.5 cm, fluid velocity = 1.4 cm·s-1 and tubing 
length before ROI (i.e., pre-ROI length) = 8.5 cm. To screen the dependency of the coefficient on all 
these variables, the parameters were changed one at a time while keeping all others unchanged: SWNT 
concentration changed to 0.025 mg·ml
-1
, SWNT fluorescence QY changed to 5.0%, tubing diameter 
changed to 380 m, ROI length changed to 1.25 cm, fluid velocity changed to 0.14 cm·s-1 and pre-ROI 
length changed to 19.5 cm. Under each combination of settings, the NIR-II fluorescence intensity within 
the selected ROI was plotted as a function of time from immediately after injection to the time when 
intensity plateaued. Then NIR-II intensity values were normalized against the maximum intensity (plateau 
intensity) within the ROI time traces. Linear fit was then performed on the linear rise of each normalized 
plot to obtain a slope in %·s
-1
. The intensity increase rate (slope) in %·s
-1
 was then used to divide the 
velocity in cm·s
-1
 to obtain the intensity-to-velocity conversion coefficient in cm·%
-1
. For numerical 
simulation, a tubing linear flow model with axial mixing was adapted from a previous publication.
29
 A 
sigmoidal function with time and velocity dependence was used to simulate NIR-II intensity distribution 
at the flow front upon mixing using MATLAB software. The flow front function F(x,v,t) was given 
analytically by: 
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which was then plotted against time (Fig. S5l-r). The linear rise region was fit to a linear equation, and 
the slope was used to divide the velocity, giving the intensity-to-velocity conversion coefficient: 
.
( )norm
v
Coeff
I t
t


  
Ultrasound for quantifying blood flow in femoral artery. Ultrasound measurements were performed 
using a linear real-time transducer (40 MHz) connected to a Vevo 2100 ultrasound system (VisualSonics). 
The femoral artery was identified employing Duplex-ultrasonography (B-Mode and power Doppler). 
Flow velocity profiles were recorded by cw-Doppler imaging. Velocity-time integrals (VTI) and cardiac 
cycle length (CL) were measured using the Vevo 2100 device software. Arterial diameter (d) was known 
for each animal from previous NIR-II imaging. Femoral flow (F) was calculated as: F = Stroke volume 
(SV)* heart rate (HF) = arterial cross-sectional area (CSA) * VTI * HF = π*(d/2)2 * VTI * 60,000 / CL 
and averaged from three cardiac cycles. 
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Figure S1. Chemical composition and cytotoxicity of SWNT-PEG-IRDye-800 conjugate. (a) Normalized 
IRDye-800 fluorescence for free IRDye-800 and SWNT-PEG-IRDye-800 at the same concentration of 
IRDye-800, suggesting the photoluminescence of IRDye-800 was quenched by ~60% due to the 
attachment to SWNTs through the PEG-chains. Inset pictures on top are corresponding 
photoluminescence images taken in the NIR-I window. (b) UV-Vis-NIR absorption spectrum of SWNT-
PEG-IRDye-800 conjugate taken in a 1 mm cuvette, where the OD values at 650 nm and 785 nm are used 
for calculating the average number of SWNT and IRDye-800 molecules in SWNT-PEG-IRDye-800 
conjugate. (c) Calculated number of SWNT and IRDye-800 molecules in each SWNT-PEG-IRDye-800 
conjugate, indicating on average 167 IRDye-800 molecules on each SWNT backbone. The large number 
of IRDye-800 molecules attached to SWNTs ensured sufficient NIR-I emitters despite fluorescence 
quenching of IRDye-800 of ~60% in a. (d) Determination of half maximal inhibitory concentration 
(IC50) of SWNTs for endothelial cells. Original data (black squares) were fitted to sigmoidal function, 
revealing an IC50 value of 0.1778±0.0237 g/L. Errors bars reflect the standard deviation of relative 
endothelial cell viability values from 3 wells of cells incubated at the same SWNT concentration. 
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Figure S2. Differentiation of femoral artery and vein inside healthy, control hindlimbs of Mouse C2–4 
(a–f) and ischemic hindlimbs of Mouse I2–3 (g–j). (a,c,e,g,i) Time course NIR-II fluorescence images 
showing hindlimb blood flow labeled by SWNT fluorescent tags. (b,d,f,h,j) PCA overlaid images based 
on the first 200 frames (37.5 s post injection) of each mouse, where arterial vessels are shown in red, 
while venous vessels are shown in blue. The scale bars all indicate 2 mm. 
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Figure S3. Differentiation of femoral artery and vein inside an ischemic hindlimb of Mouse I1 based on a 
longer post-injection imaging time. (a–h) Time course NIR-II fluorescence images showing hindlimb 
blood flow labeled by SWNT fluorescent tags. Note that femoral vein does not show up until after 2 min 
due to reduced blood flow of ischemia. (i) PCA overlaid image based on 1320 frames (up to 247.5 s post 
injection) of the mouse, where arterial vessels are shown in red, while venous vessels are shown in blue. 
The scale bar indicates 2 mm. 
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Figure S4. Arterial blood velocity analysis on the hindlimbs of ischemic Mouse I2 (a-d) and I3 (e–h). 
(a,e) NIR-II fluorescence images showing the flow front labeled by SWNT fluorescent tags. (b,f) 
Distance travelled by the flow front plotted as a function of time. (c,g) Normalized NIR-II signal in the 
femoral artery plotted as a function of time. (d,h) Linear correlation between the artery blood velocity and 
NIR-II fluorescence increase in the corresponding artery area. Scale bars in a,e indicate 5 mm and the 
intensity scale bars range from 0 to 1.   
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Figure S5. Variable dependency study of the intensity-to-velocity conversion coefficient based on both 
experimental (a-j) and simulation (l-r) results of the tubing flow setup (k). To find which variable(s) 
influence(s) the value of the coefficient, six possible parameters are changed one at a time from the 
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standard settings while keeping all other parameters unchanged. The standard settings are given by: 
SWNT concentration = 0.10 mg/mL, SWNT fluorescence quantum yield (QY) = 2.5%, tubing diameter = 
760 m, tubing length within ROI (i.e., ROI length) = 2.5 cm, fluid velocity = 1.4 cm/s and tubing length 
before ROI (i.e., pre-ROI length) = 8.5 cm. (a-c) NIR-II fluorescence images of SWNTs flowing through 
the tubing at 4.69 s, 5.25 s and 6.56 s post injection. Scale bar indicates 5 mm. (d-j) Experimental 
normalized NIR-II intensity increase curve as a function of time when: at the standard settings (d), only 
the SWNT concentration is reduced by 4 times (e), only the QY of SWNT is increased by 2 times (f), 
only the tubing diameter is reduced by 2 times (g), only the ROI length is reduced by 2 times (h), only the 
fluid velocity is reduced by 10 times (i), and only the pre-ROI is increased by 2 times (j). A linear fit 
based on the onset increase in each case gives a coefficient of 0.0778 cm/%, 0.0739 cm/%, 0.0756 cm/%, 
0.0766 cm/%, 0.0789 cm/%, 0.0757 cm/% and 0.1648 cm/%, respectively. Note the coefficient remains 
invariant except in the case of a change in the pre-ROI length. (k) A schematic drawing of the tubing flow 
experiment setup, where all six parameters are labeled. The same setup is used in the numerical 
simulation, and the flow front is simulated by a sigmoidal function, the shape of which is dependent of 
both time and fluid velocity, based on a tubing flow model with axial mixing.
1,2
 (l-r) Simulational 
normalized NIR-II intensity increase curve as a function of time when at the standard settings (l), only the 
SWNT concentration is reduced by 4 times (m), only the QY of SWNT is increased by 2 times (n), only 
the tubing diameter is reduced by 2 times (o), only the ROI length is reduced by 2 times (p), only the fluid 
velocity is reduced by 10 times (q), and only the pre-ROI is increased by 2 times (r). A linear fit based on 
the onset increase in each case gives a coefficient of 0.0730 cm/%, 0.0730 cm/%, 0.0730 cm/%, 0.0730 
cm/%, 0.0780 cm/%, 0.0722 cm/% and 0.1701 cm/%, respectively. Note the coefficient remains invariant 
except in the case of a change in the pre-ROI length. (s) A bar chart summarizing the conversion 
coefficients derived from experimental results (red bars) and simulation (blue bars), with comparison to 
the coefficient derived from the femoral arterial flow in mice (green dashed line), showing the conversion 
coefficient invariant of SWNT concentration, SWNT quantum yield, tubing diameter, ROI length and 
fluid velocity, while only influenced by the pre-ROI length.  
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Figure S6. Reproduced femoral artery blood flow quantification in three healthy, control nude mice 
(Mouse C2–4). (a) Normalized NIR-II signal in the femoral artery plotted as a function of time, revealing 
a blood velocity of 5.02±0.39 cm/s after conversion for Mouse C2. (b) Power Doppler of femoral artery 
blood flow in Mouse C2 shown in the top graph, revealing an average blood velocity of 5.96±0.23 cm/s, 
based on the velocity time integral (VTI) of three cardiac cycles as shown by pulsed wave Doppler in the 
bottom graph. (c) Normalized NIR-II signal in the femoral artery plotted as a function of time, revealing a 
blood velocity of 4.58±0.26 cm/s after conversion for Mouse C3. (d) Power Doppler of femoral artery 
blood flow in Mouse C3 shown in the top graph, revealing an average blood velocity of 4.89±0.27 cm/s, 
based on the VTI of three cardiac cycles as shown by pulsed wave Doppler in the bottom graph. (e) 
Normalized NIR-II signal in the femoral artery plotted as a function of time, revealing a blood velocity of 
5.90±0.35 cm/s after conversion for Mouse C4. (f) Power Doppler of femoral artery blood flow in Mouse 
C4 shown in the top graph, revealing an average blood velocity of 6.49±0.24 cm/s, based on the VTI of 
three cardiac cycles as shown by pulsed wave Doppler in the bottom graph. 
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